Technology from a Mount Sinai Startup (Cardea Sciences) That Will Improve Outcomes for Cardiac Patients Wins the NYC Life Science Innovation Showcase
July 18, 2017 – Technology for identifying at-risk atrial fibrillation (AFib) patients was chosen as the winner of the inaugural Alexandria LaunchLabs Scholarship Award, which recognizes excellence in health care technology, entrepreneurship and business competencies. The technology, developed by a Mount Sinai …
Breathing in a New Gene Therapy to Treat Pulmonary Hypertension
June 12, 2017- Mount Sinai has partnered with Theragene Pharmaceuticals, Inc. to advance a novel airway-delivered gene therapy for treating pulmonary hypertension (PH), a form of high blood pressure in blood vessels in the lungs that is linked to heart failure. If …
Mount Sinai, Pfizer Renew Research Collaboration, Building on Strong Foundation
June 28, 2017 – The Icahn School of Medicine at Mount Sinai and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) recently announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid …
Treating Depression with Software: Technology from Mount Sinai Steps into the Digital Healthcare Universe
June 7, 2017 – A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to initial …
Engineering New Anti-Cancer Drugs from Old Medicines
May 25, 2017 – An interdisciplinary collaboration including 45 researchers has discovered a new class of drug candidates that activates the tumor suppressor protein PP2A. These new compounds have been shown to inhibit the growth of lung cancer tumors in mice, and have …
RGFP996; A SPECIFIC HDAC3 INHIBITOR FOR TREATING ACUTE SPINAL CORD INJURY
There are approximately 12,500 new cases of acute SCI (spinal cord injury) each year in the United States, with that number expected to rapidly increase with the rise in the aging population. The only current treatment for SCI, albeit controversial, is the use …
Mount Sinai and Stony Brook Announce Affiliation
August 11, 2016 – Stony Brook Medicine and the Mount Sinai Health System today announced that they are entering into an affiliation agreement that includes collaboration on research, academic programs and clinical care initiatives, effective immediately. The institutions launched the partnership to heighten …
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
June 22, 2016 – Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn …
Mount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
May 3, 2016 – Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has signed an investigator initiated clinical trial …
Takeda Launches Multi-Year Research Partnership with Leading Inflammatory Bowel Disease Institutions
March 31, 2016 – Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), today announced a multi-year research partnership with two world leading academic centers with a proven long-term commitment to inflammatory bowel disease (IBD) research and care. The partnership, with the University of Chicago and the …